Compugen

Yahoo Finance • 11 months ago

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10... Full story

Yahoo Finance • 2 years ago

Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023

HOLON, Israel, May 11, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will host a virtual DNAM-... Full story

Yahoo Finance • 2 years ago

Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript

Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Fourth Quarter and Full Year 2022 Results Conference Call. At this time,... Full story

Yahoo Finance • 2 years ago

Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview

HOLON, Israel, Jan. 23, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat Cohen-Dayag, Ph.D., President and CEO, and a... Full story

Yahoo Finance • 2 years ago

Why Shares of Compugen Rose 16.5% on Wednesday

Shares of Compugen (NASDAQ: CGEN), a clinical-stage biotech company that specializes in immunology therapies to treat cancer, saw its shares rise 16.5% on Wednesday. The stock closed on Tuesday at $1.03, then opened on Wednesday at $1.01,... Full story

Yahoo Finance • 2 years ago

Why Compugen Stock Crumbled Today

Stocks in the ever-volatile biotech sector have many ups and downs, and Monday wasn't one of the ups for Compugen (NASDAQ: CGEN). The cancer treatment developer published its latest set of quarterly results, and investors showed their disp... Full story

Yahoo Finance • 2 years ago

Compugen to Release Third Quarter 2022 Results on Monday, November 14, 2022

HOLON, Israel, Oct. 31, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company will release its third quarter 2022... Full story

Yahoo Finance • 2 years ago

Compugen to Present New Clinical Data at ESMO-IO

Clinical data from COM701/nivolumab ± BMS-986207 combination studies in patients with platinum resistant ovarian cancer Clinical data from COM701±nivolumab study in patients with metastatic NSCLC who received prior immune checkpoints HOLO... Full story

Yahoo Finance • 3 years ago

Compugen Announces CFO Departure

HOLON, Israel, May 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Mr. Ari Krashin, Chief Financial Officer and Chie... Full story

Yahoo Finance • 3 years ago

Compugen (NASDAQ:CGEN) shareholders have endured a 61% loss from investing in the stock a year ago

Compugen Ltd. (NASDAQ:CGEN) shareholders should be happy to see the share price up 16% in the last month. But that isn't much consolation to those who have suffered through the declines of the last year. Specifically, the stock price slipp... Full story

Yahoo Finance • 3 years ago

UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health

UnitedHealth Group Incorporated’s UNH health service business, branded as Optum, recently acquired Refresh Mental Health, the operator of a vast network of mental health and other centers, per Axios. The financial details of the deal are y... Full story